LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

3.43

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.35

Max

3.59

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Aktsiakasum	-0.21
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+227.03% upside

Turustatistika
By TradingEconomics
Turukapital	330M 877M
Eelmine avamishind	3.43
Eelmine sulgemishind	3.43

Uudiste sentiment

By Acuity

50%

165 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. dets 2025, 17:29 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19. dets 2025, 16:47 UTC

Suurimad hinnamuutused turgudel

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19. dets 2025, 16:10 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19. dets 2025, 22:33 UTC

Tulu

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19. dets 2025, 22:19 UTC

Tulu

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19. dets 2025, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 21:44 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 21:38 UTC

Tulu

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19. dets 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19. dets 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19. dets 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19. dets 2025, 18:00 UTC

Market Talk

Tulu

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19. dets 2025, 17:41 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 17:24 UTC

Market Talk

Tulu

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19. dets 2025, 16:29 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19. dets 2025, 16:20 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19. dets 2025, 16:19 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19. dets 2025, 16:18 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19. dets 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. dets 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19. dets 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 16:04 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19. dets 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19. dets 2025, 15:09 UTC

Tulu

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

227.03% tõus

12 kuu keskmine prognoos

Keskmine 11.25 USD 227.03%

Kõrge 15 USD

Madal 8 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

165 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.